Skye Bioscience (SKYE) 10-Q2020 Q1 Quarterly report

Filed: 8 May 20, 3:37pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: absent, accrual, acute, afforded, Aid, alleviate, altered, announced, aware, Bank, border, burn, China, committee, Concurrently, consummation, cooperation, defer, deferred, disbursed, Disbursement, discretion, dissipated, distinct, documentation, documented, Doug, drawdown, drawn, duly, duration, elevating, elevation, employee, employment, enacted, enactment, exposure, forgiven, franchise, fundraising, gave, governmental, headcount, herewith, hyperactivity, IND, individual, Lender, lieu, main, met, mimicking, modified, month, mortgage, negotiate, neurologic, nonessential, Notably, notification, oldest, ongoing, outbreak, pandemic, partially, Paycheck, payroll, potency, PPP, pre, prepay, prepayment, prorated, pushing, recruitment, Relief, remove, rent, retention, Rule, safety, salary, SBA, Science, sector, shifted, Simplification, Small, social, sourced, sourcing, spread, strain, suppressive, thereunto, timeframe, toxic, travel, twelve, ultimate, undersigned, unknown, unprecedented, unrestricted, unvested, volunteer, Wuhan

Removed: absence, accredited, Albany, allocating, allocation, amounting, antidilution, antidilutive, assigned, bearing, canceled, Capitalization, clarification, Codification, compounding, content, convert, cumulative, death, difficulty, disability, discretionary, entitled, entry, expedient, expired, extensive, extinguished, free, immaterial, indefinite, insufficient, lease, lower, lump, mandatorily, manner, matured, modification, Molecular, navigating, Noncontrolling, noncurrent, nonpublic, par, pending, placement, practical, procurement, ramping, recognition, recognize, remained, renewable, Replacement, represented, residual, satisfied, Scope, standing, Type, utilize, wholly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SKYE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350,

as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Emerald Bioscience, Inc. a Nevada corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Brian Murphy, Chief Executive Officer of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

/s/ Brian Murphy

Brian Murphy

Chief Executive Officer

May 8, 2020

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.